Stock Market & Financial Investment News

News Breaks January 30, 2013 16:03 EDT SCLN, SNY SciClone announces product promotion agreement renewal with Sanofi in China SciClone (SCLN) announced that it has successfully negotiated renewals of its exclusive product promotion agreement with Sanofi (SNY) for the China market. Under the terms of the Sanofi agreement, SciClone, through its wholly owned subsidiary, Novamed Pharmaceuticals, exclusively promotes four key products: the anti-epileptic Depakine; the hypnotic Stilnox; the ACE inhibitor Tritace and Xatral, an alpha-1 adrenergic blocker used to treat benign prostatic hyperplasia or BPH. Depakine revenues rank second among SciClone's revenue-generating products and during the last three years under the promotional agreement, sales have increased significantly on an annual compounded basis. As the set of current agreements will expire between the end of 2012 and June 30, Sanofi and Novamed have decided to group the products and renew their agreement till December 31, which may be further extended should both parties find agreement under the terms of the contract extension. News For SCLN;SNY From The Last 14 Days Check below for free stories on SCLN;SNY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 23, 2013 08:18 EDT SNY Merrimack completes enrollement in a Phase 2 study of MM-121 with Sanofi Subscribe for More Information May 21, 2013 07:44 EDT SNY Sachs Associates to host a forum Subscribe for More Information May 20, 2013 17:26 EDT SNY Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement' Subscribe for More Information 11:27 EDT SNY Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva Subscribe for More Information May 17, 2013 08:03 EDT SNY Sanofi reports positive topline results from pivotal Phase III Jakarta study Subscribe for More Information 05:18 EDT SNY Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint Subscribe for More Information May 16, 2013 16:04 EDT SCLN SciClone, Zensun enter licensing agreement for Neucardin Subscribe for More Information 16:02 EDT SCLN SciClone sees Q1 EPS 7c, two estimates 9c Subscribe for More Information May 15, 2013 15:16 EDT SNY Sanofi systemic sclerosis treatment designated for orphan drug status Subscribe for More Information 05:39 EDT SNY Sanofi, Regeneron announce patient enrollment in two Phase 3 trials Subscribe for More Information May 13, 2013 09:44 EDT SNY Several companies reportedly interested in buying Adcock Ingram, Globes says Subscribe for More Information 07:30 EDT SNY TechConnect to host a summit 2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. May 10, 2013 11:48 EDT SNY Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.